Do you want to read an article? Please log in or register.
Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study
Asthma
RECOMMENDED
Related content
RECOMMENDED
Asthma
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy.
Llanos JP, Ortega H, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B
doi: 10.2147/JAA.S236609.
COMMENTED
Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data
J Asthma.
Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B
doi: 10.1080/
RECOMMENDED
Asthma
Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma
★ 3
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Kavanagh JE, Hearn AP, Dhariwal J, Gráinne d'Ancona, Douiri A, Roxas C, Fernandes M, Green L, Thomson L, Nanzer AM, Kent BD, Jackson DJ
doi: 10.1016/j.chest.2020.08.2083.
Asthma
Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study
J Asthma.
Albers FC, Müllerová H, Gunsoy NB, Shin JY, Nelsen LM, Bradford ES, Cockle SM, Suruki RY
doi: 10.1080/02770903.
RECOMMENDED
Asthma
Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
doi: 10.1016/j.chest.2020.03.042.
RECOMMENDED
Asthma
Real-world mepolizumab in the prospective severe asthma REALITI-A study - initial analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir J.
Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, Valero A, Gemzoe K, Maxwell A, Joksaite S, Yang S, Howarth P, Van Dyke MK
doi: 10.1183/13993003.00151-2020.
RECOMMENDED
Asthma
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
J Allergy Clin Immunol.
Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, Bradford ES, Gilson M, Price RG, Yancey SW, Ortega H
doi: 10.1016/j.jaci.2018.09.033.
RECOMMENDED
Asthma
Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 3
Recommended by
Dr Marcus Hesse, Faculty Member
J Asthma Allergy
Kayser MZ, Drick N, Milger K, Fuge J, Kneidinger N, Korn S, Buhl R, Behr J, Welte T, Suhling H
doi: 10.2147/JAA.S319572
RECOMMENDED
Further Publications
The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med
McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, Pavord ID, Heaney LG, Medical Research Council: Refractory Asthma Stratification Programme (RASP-UK Consortium).
doi: 10.1016/S2213-2600(21)00004-7